Broadcom stock approached a buy point following news reports that the fabless chipmaker is designing an AI server chip for Apple.

Shares of AbbVie Inc. ABBV slipped 0.74% to $174.37 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6,084.19 and ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

Aristocrats span all sectors, with BEN topping yields. Read why its strong dividend history and low price make it a December ...

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose ...

Johnson & Johnson submitted to the FDA trial data that it hopes will lead to the first approved treatment for smoldering myeloma. Also in the news: 3D mammograms gain popularity; companies want to ...

Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...

BofA reinstated coverage of AbbVie (ABBV) with a Neutral rating and $191 price target AbbVie is a relatively “quiet” stock with durable ...

This report offers insights into recent health news, encompassing advancements in Parkinson's and cancer treatments, ...